Search

alpha-Pyrrolidinononanophenone

Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

SB-743921

Retaspimycin

Efavaleukin alfa

It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease). … Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

GC5107

GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.

Danvatirsen

Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

Bisphosphocin Nu-3

Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

NasoVAX

As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313].

Nimotuzumab